Heterogeneous responses of IM19 anti-CD19 CAR T-cell therapy in refractory systemic lupus erythematosus: an open-label pilot study and a mini-review | Synapse
March 3, 2026
Heterogeneous responses of IM19 anti-CD19 CAR T-cell therapy in refractory systemic lupus erythematosus: an open-label pilot study and a mini-review
Puntos clave
Immune responses varied significantly among patients receiving CAR T-cell therapy for lupus.
Approximately 32% of patients showed positive biomarkers indicating therapy efficacy.
Assessment was conducted through an open-label pilot study with multiple outcomes tracked.
Findings suggest the need for tailored approaches in treating systemic lupus erythematosus patients.